P&G beats earnings forecast; Alliance Pharma buys AZ anti-malarial brands;

 @FiercePharma: More on "how not to insider trade," with Bristol-Myers exec as exhibit A, from The Wall Street Journal. More | Follow @FiercePharma

> Procter & Gamble ($PG), which has attracted a large investment from William Ackman, beat earnings expectations. Story

> Alliance Pharma has ponied up £4.2 million ($6.5 million) for three anti-malarial brands from AstraZeneca ($AZN), Paludrine, Avloclor and Savarine, which it intends to sell mostly in Europe. Story  

> Biotech expert Eric Tomlinson is the new leader of North Carolina's Piedmont Triad Research Park. Story  

> Walgreen's fight with pharmacy benefits company Express Scripts cost it more sales than expected in July, partly accounting for a 7% slip. Story

> Ireland's Warner Chilcott ($WCRX) had lower revenue and earnings in its last quarter as slower U.S. sales and loss of a patent undercut its performance. Story

> China's ShangPharma has hired an adviser to evaluate a buyout offer from its CEO. Release

Medical Device News

@FierceMedDev: Globus scales back its IPO pricing, now trading under GMED. More | Follow @FierceMedDev

 @MarkHFierce: Thoratec reported a Q2 loss but is banking on continued sales growth to carry the year. More | Follow @MarkHFierce

 @DamianFierce: Study: U.S. access to new devices no slower than EU's. More | Follow @DamianFierce

> Study: U.S. access to new devices no slower than EU's. Report

> CA hospital accused of testing Stryker tech without patient consent. Article

> FDA whacks Philips unit with Class I ventilator recall. News

Biotech News

 @FierceBiotech: Yesterday's most popular story: Analyst reads last rites after heart failure scuttles Bristol hepatitis C study. Story | Follow @FierceBiotech

 @JohnCFierce: Bankers tally torrid pace for biotech M&A as hungry suitors pounce. More | Follow @JohnCFierce

 @RyanMFierce: A record for GSK? Asks for FDA approval for targeted melanoma treatment roughly 3 years after hitting the clinic. More | Follow @RyanMFierce

> J&J's boost in Doxil supply benefits study of Endocyte/Merck drug. Article

> Biotech startup Atterocor grabs $16M A round for cancer compound. More

> H1 venture deals: Celladon moves up in the rankings. Update

> Burrill & Co. boosts latest life sciences fund to $505M. News

> GSK races to regulators for approvals of new skin cancer drugs. Article

And Finally... The FDA has approved a drug with digestible sensors that can tell doctors if you have taken it. Story

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.